English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
真正的赋能者——爱克发医疗在2026年欧洲放射学大会上展现影像创新力量
Jan 15, 2026 16:00 HKT
真正的賦能者——愛格法醫療於2026年歐洲放射學會議(ECR)展現影像創新風采
Jan 15, 2026 16:00 HKT
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT
吉因加啟動港股IPO:AI驅動全鏈條精準醫療 構築差異化技術壁壘
Dec 30, 2025 20:14 HKT
吉因加启动港股IPO:AI驱动全链条精准医疗 构筑差异化技术壁垒
Dec 30, 2025 19:28 HKT
Avantor Appoints Gladys Wang as Vice President, Bioprocessing Commercial, Asia, Middle East & Africa
Dec 24, 2025 12:20 HKT
青岛国资+双管线驱动!华芢生物(02396.HK)破局PDGF稀缺赛道 锚定国配核心机遇
Dec 16, 2025 10:39 HKT
青島國資+雙管線驅動!華芢生物(02396.HK)破局PDGF稀缺賽道 錨定國配核心機遇
Dec 16, 2025 10:39 HKT
康哲藥業(867.HK/8A8.SG):創新藥口服JAK1抑制劑Povorcitinib在中國獲納入「突破性治療品種」
Dec 16, 2025 08:07 HKT
康哲药业(867.HK/8A8.SG):创新药口服JAK1抑制剂Povorcitinib在中国获纳入"突破性治疗品种"
Dec 16, 2025 08:06 HKT
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份
Dec 15, 2025 16:59 HKT
云顶新耀发布2030战略规划 管理层及主要股东增持超3800万港元股份
Dec 15, 2025 16:59 HKT
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
Dec 15, 2025 16:59 HKT
国资护航+技术壁垒+优质保荐 华芢生物(02396.HK)PDGF管线直指18A赛道确定性价值
Dec 15, 2025 11:05 HKT
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值
Dec 15, 2025 09:28 HKT
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT
云顶新耀与海森生物签署商业化服务协议及授权许可协议 推动商业化协同与多领域布局
Dec 12, 2025 14:35 HKT
雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局
Dec 12, 2025 14:35 HKT
康哲藥業(0867)抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理
Dec 11, 2025 20:01 HKT
Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: